HOLX's New Offerings Likely to Revive Stock Amid Macro Woes
Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new global markets.
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.
Deciphering Hologic (HOLX) International Revenue Trends
Examine the evolution of Hologic's (HOLX) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Hologic (HOLX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance
HOLX's fiscal 2025 first-quarter results reflect the strength of its Molecular Diagnostics business.
Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX ) Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Mike Watts - Corporate Vice President, IR Steve MacMillan - Chairman, President and CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Anthony Petrone - Mizuho Group Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Casey Woodring - JP Morgan Tejas Savant - Morgan Stanley Ryan Zimmerman - BTIG Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Andrew Cooper - Raymond James Operator Good afternoon. And welcome to the Hologic's First Quarter Fiscal 2025 Earnings Conference Call.
Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) Q1 Earnings Surpass Estimates
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.98 per share a year ago.
Hologic cuts annual revenue forecast on weak demand for breast health products
Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company's shares down 5% after the bell on Wednesday.
Hologic (HOLX) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Countdown to Hologic (HOLX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
